Trial Search Results

Stanford RAD-AT Study (Research on Anxiety and Depression - Anhedonia Treatment)

This research study is aimed at understanding behaviors and brain circuits that relate to anxiety and depression. Our goal is to learn which circuits of the brain are involved in anxiety and how these circuits might affect daily functioning.

This study has recently added an additional treatment component: participants undergo a 12 week course of either Pramipexole medication or rTMS therapy (explained below). The ultimate goal of the study is to offer participants experiencing anxiety and depression a treatment that is alternative to ones that have failed them in the past, and to apply the knowledge we gain from investigating the brain circuits involved in anxiety and depression to help personalize treatments.

We invite anyone who has recently experienced any symptoms of anxiety and/or depression to participate (no diagnosis is required to participate).

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Drug: Pramipexole Oral Tablet


Inclusion Criteria:

   - Recent experiences of anxiety and/or depression

   - Ages 18-65

Exclusion Criteria:

   - Specific psychiatric medications (case-by-case basis)

   - A diagnosis of Bipolar 1 Disorder, Schizophrenia, or Obsessive Compulsive Disorder

   - Any of the following medical conditions: Parkinson's disease; liver or kidney disease;
   history of epilepsy or seizures; history of cardiovascular disorders (specifically
   orthostatic hypotension)

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Nowreen Chowdhry, B.S.
(650) 497-6480